Purpose: Ixabepilone (Ixempra; BMS-247550) is an epothilone B analog and nontaxane microtubulestabilizing compound with clinical activity in a range of solid tumors. This phase II study was conducted to assess the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma.
In 2007 in the United States, ∼51,000 people had a diagnosis of renal cell carcinoma and almost 13,000 died from metastatic renal cell carcinoma (1) . The incidence of renal cell carcinoma has increased over time (2) (3) (4) . Historically, no single cytotoxic agent or combination has consistently produced responses that justify their routine use in this group (5, 6) . For the past 20 years, before the approval of targeted therapies, interleukin 2 (IL-2) and IFN-α, alone or in combination, have been the main treatments for metastatic renal cell carcinoma. Response rates with these cytokines are low (5-20%), and median overall survival is ∼12.0 to 17.5 months (7) (8) (9) (10) (11) (12) . More recently, tumor responses have been reported with sorafenib (Nexavar, Bayer), sunitinib (Sutent, Pfizer), temsirolimus (Torisel, Wyeth), and everolimus (Affinitor, Novartis), with increases in progression-free survival and or with modest improvement of overall survival (11, (13) (14) (15) . However, because none of these therapies can be considered curative, there remains a need to develop alternative strategies.
Ixabepilone is a semisynthetic analog of the natural product, epothilone B, a member of a novel class of nontaxane microtubule-stabilizing agents. It exerts antiproliferative effects by binding tubulin and stabilizing microtubules, affecting mitotic arrest, and also impairing microtubule trafficking (16) (17) (18) . Epothilones are poor substrates for P-glycoprotein and exhibit activity in paclitaxel-resistant cell lines and paclitaxel-resistant tumor models (16, (19) (20) (21) . A previous phase I study established ixabepilone administered at a dose of 6 mg/m 2 for 5 consecutive days every 3 weeks as the recommended phase II dose. Neutropenia was dose limiting. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting (22) . Because of encouraging results and tolerable toxicity profiles in these phase I studies, this phase II trial was initiated to determine the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma.
Patients and Methods
Eligibility. Eligible patients had to be >18 y, with histologically or cytologically proven renal cell carcinoma (clear cell, papillary, chromophobe, collecting duct, and medullary) and disease that could be evaluated by Response Evaluation Criteria in Solid Tumor (RECIST; ref. 23 ). Additional criteria for entry included an Eastern Cooperative Oncology Group performance status of 0 to 2; a life expectancy of at least 3 mo; adequate bone marrow (absolute neutrophil count > 1.5 × 10 9 /L and platelet count > 100 × 10 9 /L), hepatic, and renal function. Exclusion criteria included previous chemotherapy. Of note, enrollment began in 2002, several years before sorafenib (Nexavar, Bayer), sunitinib (Sutent, Pfizer), or temsirolimus (Torisel, Wyeth) had been approved by the Food and Drug Administration for metastatic renal cell carcinoma. Patients with brain metastasis were excluded, unless they had been appropriately treated and stable for at least 6 mo.
Study design and treatment modifications. The study was approved by the Institutional Review Board of the Center for Cancer Research (intramural program) of the National Cancer Institute (Bethesda, Maryland). All patients signed Institutional Review Board-approved written informed consent. Ixabepilone was provided by the Cancer Therapy Evaluation Program, National Cancer Institute, through a cooperative agreement with Bristol-Myers Squibb. Ixabepilone was administered at a dose of 6 mg/m 2 i.v. during a 1-h infusion daily for 5 consecutive days every 3 wk. Diphenhydramine 50 mg and ranitidine 50 mg were administered i.v. 30 to 60 min before the administration of ixabepilone as prophylaxis against reactions to cremophor XL. Prophylactic antiemetics were not administered routinely. Adverse events were coded according the National Cancer Institute Common Toxicity Criteria version 2.0. Cycles were extended to 28 and 35 d on occasion to accommodate grade 2 neuropathy.
Response assessment. Measurable disease was assessed by computerized tomography scans (CT) using RECIST guidelines (23) , with baseline imaging within 4 wk of enrollment and restaging after every two cycles.
Statistical design and methodology. This protocol was designed to evaluate the efficacy of ixabepilone and was conducted using a two-stage optimal design to rule out a low 5% response rate in favor of a 20% response rate (24) . Patients were grouped according to histology (clear cell, papillary, or other). If one or more patients had a response, accrual continued until a total of 37 evaluable patients had been enrolled (clear cell group was the only cohort expanded to 37 patients).
An amendment in 11/03 halted accrual while it sought to increase the clear cell cohort to 74 patients to examine the activity of ixabepilone in patients with wild-type VHL, based on an assumption (not realized) of 50% wild-type and 50% mutant VHL.
Correlative studies. Patients with tumors that could safely have a biopsy done under local anesthesia had core biopsies obtained at baseline and ∼2 to 6 h after the cycle 1 day 5 dose of ixabepilone treatment. Assessment of target engagement and sequencing of VHL were done (see supplementary information).
Results
Patient characteristics. Between February 2002 and April 2007, 87 patients with metastatic renal cell carcinoma were enrolled onto this study. The baseline characteristics and patient's previous therapy are summarized in Table 1 . The median age was 57.1 years; most were male and Caucasian with Eastern Cooperative Oncology Group performance status of 0 to 1. Ninety percent had undergone a cytoreductive nephrectomy. Half of the patients had received systemic treatment, including IL-2, IFN, thalidomide, a vaccine, and other therapies, whereas the other half had not received previous systemic treatment. Eighty-six percent of patients' tumors were of clear cell histology. Patients had extensive tumor burden at baseline, with a median of 21.7 cm of tumor (sum of longest diameters of all tumors), of which 10.5 cm was evaluated by RECIST. The mean number of metastatic sites was three, with most patients presenting with lung involvement, as well as lymphadenopathy in the chest, abdomen, or both. Other common sites of disease included the liver, bones, and soft tissue. (Note: a site of metastatic disease, such as
Translational Relevance
This study reports the results of a clinical trial with ixabepilone (Ixempra) in patients with advanced metastatic renal cell carcinoma. Ixabepilone is a novel microtubule-targeting agent recently approved by the Food and Drug Administration for the therapy of metastatic breast cancer. The current study represents a large single-institution trial in patients with renal cell carcinoma with mature data, including overall survival. It also reports interesting translational analyses that show that this agent consistently reaches its target in the cell and affects microtubule stabilization. Given the recent interest in renal cell carcinoma and renewed hope that better therapies may be forthcoming, this report is interesting in that it describes activity of an agent unlike any approved to date for this still very refractory disease. Its tolerability and low toxicity make it an attractive agent to use in combination therapies. lung parenchyma, counted as one site, whether there was one nodule or 25).
Efficacy. Eighty-four of 87 patients completed two cycles. One patient with new onset hemoptysis during cycle 2 day 2 decided against further ixabepilone therapy. Another patient with significant comorbidities, including COPD and urethral obstruction, had a stent placed to relieve external obstruction of the left main stem bronchus, after which his performance status declined markedly without further treatment. A third patient with sepsis on cycle 1 day 8 refused aggressive care, fully aware of the likely outcome, and died quickly. The total number of cycles administered was 590, with a median of five cycles per patient. All patients received a dose of 6 mg/m 2 as the starting dose. Early in the conduct of the study, 19 patients (43 cycles) who tolerated the starting dose of 6 mg/m 2 well were advanced to a daily dose of 8 mg/m 2 . When it became apparent this dose often caused unacceptable fatigue, further escalations were not attempted, especially because all responses had been observed at the dose of 6 mg/m 2 . Among the 87 patients enrolled on study, the overall response rate was 12.6%. As shown in Table 2 , one patient had a complete response and 10 patients had partial responses, and a best response of stable disease for at least four cycles per RECIST criteria was confirmed in 33 patients (37.9%). Measurable responses were observed in lung, liver, soft tissue, and lymph nodes. Improvements were also seen in nontarget lesions, including bones, pleura, and skin. The waterfall plot of best tumor response in percentage change from baseline for the 84 patients who received at least two cycles and had a repeat imaging study is shown in Fig. 1 . The graph directly above the response graph depicts the total tumor burden in each patient. Together, these graphs show that the extent of response is independent of the total tumor burden or the disease measured in the RECIST evaluation (see also supplementary data for correlation with RECIST measurements). Tumor shrinkage was not confined to those with small volume disease. Stable disease was not only seen in patients with a large amount of disease, in which an increase of 20% might be more difficult to attain, given the large tumor burden at the start ( Figs. 1 and 2) .
The median time to progression was 19 weeks. For the 11 patients who achieved complete response or partial response, the median duration of response was 5.5 months. The median overall survival of the 74 patients with renal cell carcinoma Motzer grade 0 and 1 and clear cell histology was 19.25 months. This analysis was done to allow for a comparison with the published trials with sorafenib and sunitinib. Because 19 patients (25.6%) subsequently went on to receive sorafenib or sunitinib, any patient who received either of these agents had their survival arbitrarily censored 1 month after the initiation of sunitinib or sorafenib. In this way, we were sure to avoid assigning any benefit on survival to ixabepilone that could have come from other therapies. Toxicities. Toxicities are summarized in Table 3 . The median and mean absolute neutrophil count in cycle 1 was 2,945 and 2,880, respectively. The median and mean absolute neutrophil count in all cycles were 2,879 and 2,735, respectively. Only 9 of 87 patients experienced grade 4 neutropenia at the dose of 6 mg/m 2 . Only one patient had grade 3 thromobocytopenia at that dose level. Neuropathy was observed in 59% of patients. Most of these events were neurosensory and grade 1 or 2, with only 4 of 87 patients developing grade 3 sensory neuropathy or motor neuropathy. Two patients developed what seemed clinically to be an autonomic neuropathy manifested by orthostatic hypotension and syncope. Both had gradual improvement in symptoms over time after ixabepilone was discontinued. The other notable adverse events attributable to ixabepilone include alopecia (70%), fatigue, nail changes, anorexia, nausea, taste disturbance, and diarrhea. Only eight patients were removed from study because of Fig. 1 . A, tumor burden, the sum of the size of all tumor masses >1 cm. All patients shown with a tumor burden of 40 or 50 cm actually had a larger burden, but these consisted of variable number of small metastases that were not measured. B, waterfall plot of tumor response calculated using RECIST criteria. Bars, percentage change from baseline. Fig. 2 . Scans showing response in a patient with metastatic renal cell carcinoma after treatment with ixabepilone. Previous therapies included nephrectomy, metastasectomy, radiation therapy to L1, high-dose IL-2, and experimental therapy with fms-like tyrosine kinase receptor-3 (FLT3)/CD40L. The baseline scan is on the left, with a scan obtained after 17 cycles shown on the right. According to RECIST criteria, a partial response was achieved after eight cycles, but the tumor continued to shrink for 21 cycles before showing evidence of progression on cycle 26. toxicities. One episode of grade 5 febrile neutropenia (discussed above) occurred during cycle 1 in a 55-year-old gentleman with extensive disease. A second patient died while on study as a result of a brainstem infarct during a vertebral body embolization procedure done at another institution.
Correlative studies. We have previously reported target engagement with two markers of stable tubulin before and after ixabepilone treatment in cycle 1 (25) . As shown in Fig. 3 , the increases in these two markers are closely correlated, confirming the target engagement by ixabepilone (see supplementary information).
Finally, based largely on theoretical considerations that VHL mutation status could affect response to ixabepilone (26), a decision was made after some activity was observed early in the study to double the accrual, expecting that about half of the patients would present with a mutation in the VHL. The coding sequence of the VHL gene in 32 patients was sequenced for mutations. The primers used in the PCR and sequencing reactions are listed in Supplementary Table 1 and shown schematically in Supplementary Fig. 3 . To validate our assay, we isolated DNA from eight renal cell carcinoma cell lines (four with wild-type VHL and four with mutant VHL) and from three renal cell carcinoma tumors and three pheochromocytoma tumors from patients with a diagnosis of VHL. Sequencing of reverse transcriptase-PCR products from these cell lines and tumors identified all 10 mutations. By comparison we detected a VHL mutation in only 1 of 32 patient samples, a 1-bp deletion at nucleotide 317 (relative to start of translation), resulting in a premature stop codon at amino acid 158 (see supplementary section).
Discussion
In the present study, we report on the activity of the microtubule-stabilizing agent, ixabepilone, in patients with metastatic renal cell carcinoma. The objective response rate as assessed by RECIST is 12.6%, with a median overall survival of 19.25 months in the 74 patients with Motzer grade 0/1 and clear cell histology. Although these results must be confirmed, they cannot be ascribed to enrollment of a select group of patients with a favorable prognosis given the large number of patients and the advanced disease at presentation, with a median tumor burden of >21 cm and an average of three sites of metastatic disease. With the approval of five agents for metastatic renal cell carcinoma in the past 4 years and the knowledge that at least three, if not all five, have very similar mechanisms of action, the identification of an agent from a totally distinct class of chemotherapeutics is, in our opinion, of interest and worthy of further evaluation.
Although the potential value in metastatic renal cell carcinoma of ixabepilone lies in its different mechanism of action and not as an agent that competes with drugs already approved for renal cell carcinoma, it is useful nevertheless to compare its activity with the already approved chemotherapeutics. Although the median time on therapy was 19 weeks, we would note that some patients were removed from study before meeting the criteria for RECIST-defined progression. This occurred primarily before the approval of sorafenib and available information that suggested this agent was very active in metastatic renal cell carcinoma. Consequently, some patients were encouraged to seek out trials with sorafenib or later compassionate-use sorafenib when it seemed remaining on ixabepilone would not lead to a significant response. These patients thus came off study before meeting RECIST criteria for progression and could have remained on study for at least an additional 6 weeks until the subsequent scan. This approach was taken because time to progression was not an endpoint and was driven by what investigators saw as the patient's best interest. Had these patients continued on study for a minimum of six additional weeks, then the median time on ixabepilone before progression would have increased to at least 24.9 weeks, a value that compares favorably with sorafenib data showing a median TTP of 24 weeks. More importantly, the median overall survival of renal cell carcinoma Motzer grade 0 and 1 patients with clear cell histology, a cohort comparable with patients enrolled on the sorafenib and sunitinib registration trials, was 19.25 months, comparable with the 19.3 months for sorafenib (13) .
As noted in the Results section, the latter value is not affected by the few patients who received sorafenib or sunitinib because, if they received either drug for >1 month, their survival was tabulated from enrolment to 1 month after the start of sorafenib or sunitinib. But in fact, most patients either did not tolerate these drugs nor had minimal benefit, and only 2 patients exceeded the median overall survival while receiving sorafenib or sunitinib and the adjustment in survival was only meaningful in these two. Although one might argue the daily times five schedule is suboptimal in terms of convenience, we found this schedule easy to administer, well-tolerated, and acceptable to the patients, many of who traveled great distances to participate in this trial. Neurotoxicity was largely grade 1 or 2 with less than 5% grade 3 toxicity, consistent with other studies conducted with the same schedule (27, 28) , and much less than with the 30 to 40 mg/m 2 every 3 weeks schedule that has reported grade 3 neuropathy in as many as 20% or more of patients enrolled (29, 30) . The lower incidence of neurotoxicity with this regimen is reminiscent of data with the taxanes that showed a much lower incidence of neurotoxicity with a 96-hour infusion of paclitaxel (31) (32) (33) (34) (35) . If for ixabepilone, as for the taxanes, the peak concentration is important in causing peripheral neuropathy, then the lower peaks achieved with a daily for 5 days schedule might be important (36) . The lower incidence of neurotoxicity with this schedule could be considered by physicians preparing to administer ixabepilone to patients with other cancers, especially those with neurotoxicity before the start of ixabepilone. Also notable was the fact that severe myelosuppression was very uncommon. The median absolute neutrophil counts for cycle 1 and for all cycles were 2,879 and 2,735, respectively, with grade 3 thrombocytopenia recorded in only one patient. Although we recognize the patients enrolled on this clinical trial had not received previous myelosuppressive therapy, the results are nevertheless encouraging, especially if one considers this ixabepilone schedule as a building block with other agents.
Ixabepilone has been evaluated in one other phase II trial in renal cell carcinoma using a different schedule (37) . That study evaluated a dose of 40 mg/m 2 every 21 days and reported the schedule to be inactive. However, only 5 of 12 patients had clear cell renal cell carcinoma with other histology in the remaining seven, possibly explaining the different results. Alternately, the difference in schedule, daily for 5 days versus once every 3 weeks, could potentially affect tumor response. As has been previously shown in preclinical studies with the taxanes, longer or more frequent schedules of administration might be more active in slower growing tumors such as renal cell carcinoma, especially if cytotoxicity depends on what part of the cell cycle the cell is when ixabepilone is administered (38, 39) .
Kidney cancer has historically been refractory to cytotoxic agents, including the taxanes (6, 40, 41) . The ineffectiveness of chemotherapy can be ascribed, in part, to intrinsic resistance to chemotherapy. Overexpression of the drug transporter P-glycoprotein and its encoding gene, MDR-1, has been frequently cited as a mechanism of resistance. A high level of expression of MDR-1 and in vitro sensitization to Fig. 3 . Increased levels of two markers of stable tubulin, acetylated and Glu-terminated α-tubulin, were observed after the administration of ixapebilone in 84% to 92% of serial biopsies. The increased levels of these two markers were closely correlated, confirming with two different antibodies the occurrence of target engagement by ixabepilone.
vinblastine with the antagonists verapamil and quinidine have been observed in kidney cancer (42) . These findings suggest P-glycoprotein expression could explain, at least in part, the resistance of renal cell carcinoma. The epothilones represent the first antimicrotubule agents that are not P-glycoprotein substrates. Although other putative advantages of ixabepilone are being studied, to date, the only advantage that has been validated is the lack of P-glycoprotein-mediated efflux, and this may in part explain the efficacy of ixabepilone in renal cell carcinoma. That this cannot be the only explanation, but must be part of a more diversified resistance portfolio, is evidenced by the fact that target engagement was observed in most tumor samples analyzed, indicating resistance mechanisms distal to engagement of the target prevented cytotoxicity. Studies are underway to try to discern other mechanisms.
Finally, using a methodology that was validated with 10 samples whose mutations were unknown to the individual doing the analysis, we sought to determine the VHL mutation status of tumors. To our surprise, most tumors from our patients with sporadic renal cell carcinoma did not harbor VHL mutations. Using primers that generated small fragments, we were able to successfully clone all samples, even those for which we had only DNA isolated from microdissected formalin-embedded tissues. Although the significance remains to be determined, we must conclude the incidence of VHL mutations in patients with aggressive sporadic renal cell carcinoma is lower than previously thought.
In summary, ixabepilone is a potent microtubulestabilizing agent that shows some activity in metastatic renal cell carcinoma. This cytotoxic agent could be considered in combination or sequentially with other therapies, for example, bevacizumab, sorafenib, sunitinib, and pazopanib in future studies to attempt to improve the therapy of metastatic renal cell carcinoma.
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